Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$2.27
-$0.01(-0.44%)
At close: 4:00 PM EDT
$2.27
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous Close$2.28
Volume807.02K
Average Volume (3M)730.63K
Market Cap
$176.91M
Enterprise Value$101.60
Total Cash (Recent Filing)$182.76M
Total Debt (Recent Filing)$73.54M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume633,109
30 Day Avg. Volume730,626
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside417.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Agreement Enabling Outpatient DosingThe FDA agreement to allow outpatient dosing and Nkarta’s start of community-based site dosing materially improves delivery scalability and patient access. Over 2-6 months this reduces reliance on inpatient infrastructure, lowers per-treatment logistics and cost, and can speed enrollment and commercial rollout pathways.
Allogeneic "off-the-shelf" NK Cell PlatformNkarta’s allogeneic, off-the-shelf NK cell approach is a structural competitive advantage versus autologous therapies: it supports standardized manufacturing, faster treatment delivery, and potential lower COGS at scale. This platform durability underpins long-term commercial scalability if trials succeed.
Improving Free Cash Flow TrendDespite continued negative cash flow, recent positive free-cash-flow growth signals incremental operating efficiency gains. Over a medium horizon this trend can extend runway, reduce near-term dilution need, and improve negotiating leverage with partners or lenders if sustained.
Bears Say
Pre-revenue With Persistent Operating LossesNkarta has no product revenue and substantial recurring operating losses, meaning it lacks internal commercial cash generation. Over the next several months this keeps the company dependent on external funding and prolongs the timeline to positive margin sustainability and self-funded growth.
Significant Cash Burn And Financing RelianceConsistent large negative operating and free cash flows indicate ongoing high cash consumption to fund R&D and trials. This structural cash burn necessitates periodic financing, which can dilute shareholders, constrain strategic optionality, and increase execution risk over the medium term.
Eroding Equity And Negative Returns On EquityMaterial declines in equity and deeply negative ROE reflect ongoing value erosion from losses. A weaker equity base reduces financial flexibility, limits collateral for debt, and can make future financings more costly or dilutive, increasing structural risk to sustaining long-term R&D programs.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $176.91M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Aug 10, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.18.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.4.
How many shares outstanding does Nkarta have?
Nkarta has 71,624,794 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.285%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (417.62% Upside)
$11.75 (417.62% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 587.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.4%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(417.62% Upside)
Technical Analysis
Ownership Overview
20.62% Insiders
7.76% Mutual Funds
46.00% Other Institutional Investors
18.50% Public Companies and
Individual Investors